JSSH(SZ:000518)2023-08-22 16:00Financial Performance - The company's operating revenue for the first half of 2023 was ¥121,411,354.73, representing a 2.55% increase compared to ¥118,397,374.09 in the same period last year[19]. - The net loss attributable to shareholders was ¥37,775,397.48, which is a 14.72% increase in loss compared to ¥32,927,209.66 in the previous year[19]. - The net cash flow from operating activities decreased significantly by 88.63%, amounting to ¥808,121.15 compared to ¥7,105,657.94 in the same period last year[19]. - The total assets at the end of the reporting period were ¥712,555,161.73, down 3.46% from ¥738,078,462.55 at the end of the previous year[19]. - The company reported a basic earnings per share of -¥0.0367, a decrease of 14.69% from -¥0.0320 in the previous year[19]. - The weighted average return on net assets was -7.02%, compared to -5.58% in the previous year, indicating a decline in profitability[19]. - The company's revenue for the reporting period was CNY 121,411,354.73, representing a year-on-year increase of 2.55% compared to CNY 118,397,374.09[36]. - The company's R&D investment decreased by 51.85% to CNY 14,480,935.62 from CNY 30,076,280.23 in the previous year, indicating a reduction in ongoing projects[36]. - Sales expenses increased by 31.61% to CNY 65,807,996.66, attributed to increased market research and promotion efforts[36]. - The company reported a gross profit margin of approximately 28.5% for the first half of 2023, down from 30.0% in the previous year[126]. Assets and Liabilities - The total assets of the company as of the end of the first half of 2023 were CNY 715,471,458.50, slightly down from CNY 716,647,363.94 at the end of 2022[124]. - Total liabilities as of June 30, 2023, were CNY 159,179,908.88, up from CNY 144,583,108.82, representing an increase of about 10.1%[120]. - The company's total equity decreased to CNY 553,375,252.85 from CNY 593,495,353.73, a decline of approximately 6.8%[120]. - The company has no preferred shares or bonds outstanding as of the reporting date[111][120]. Cash Flow - The operating cash flow for the reporting period was CNY 808,121.15, a significant decrease of 88.63% compared to CNY 7,105,657.94 in the previous year[36]. - The company reported a cash outflow of ¥5,376,002.43 related to the repayment of lease liabilities during the reporting period[90]. - The total cash outflow from operating activities was 750,659.13 yuan in the first half of 2023, down from 1,682,891.36 yuan in the same period of 2022, indicating a reduction of approximately 55%[135]. - The total cash inflow from financing activities decreased to 27,560,000.00 yuan in the first half of 2023 from 41,302,000.70 yuan in the previous year, reflecting a decline of approximately 33.3%[136]. Research and Development - The company has five invention patents and three new drug certificates, highlighting its strong R&D capabilities[33]. - The company has invested 5.4 million yuan in research and development during the first half of 2023, reflecting a commitment to innovation[140]. - Research and development expenses decreased to CNY 14,480,935.62 in the first half of 2023 from CNY 30,076,280.23 in the same period of 2022, a reduction of about 52.1%[126]. Market and Sales - The company continues to focus on the production and sales of biopharmaceutical products, including recombinant human erythropoietin and granulocyte colony-stimulating factor injections[27]. - The company employs a sales model primarily through distributors, focusing on academic promotion and technical training to enhance product recognition[30]. - Domestic sales contributed ¥118,732,130.73, representing 97.79% of total revenue, while international sales increased to ¥2,679,224.00, accounting for 2.21%[37]. Environmental Compliance - The company is subject to strict environmental regulations and holds a valid Pollution Permit until July 14, 2027[61]. - The company has implemented measures to monitor and control emissions effectively[63]. - The company reported a stable operation of its wastewater treatment plant with a capacity of 120 tons per day, which was put into operation in December 2021 and has achieved standard discharge[65]. Corporate Governance - The company emphasizes the protection of minority shareholders' rights and has established a comprehensive corporate governance structure to ensure fair treatment[67]. - The company has set up various specialized committees within its board of directors to enhance governance and operational efficiency[67]. - The company adheres to timely and accurate information disclosure practices to protect the rights of all shareholders and stakeholders[67]. Legal Matters - The company has received a first-instance judgment dismissing all claims in a lawsuit related to securities false statements[51]. - The company reported no significant litigation or arbitration matters during the reporting period[79]. - There were no major related party transactions during the reporting period[81]. Future Outlook - Future outlook remains cautious due to ongoing market challenges and the need for strategic adjustments to improve profitability[127]. - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[142]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[146].